首页> 美国卫生研究院文献>Biomarker Research >CD34 and CD38 are prognostic biomarkers for acute B lymphoblastic leukemia
【2h】

CD34 and CD38 are prognostic biomarkers for acute B lymphoblastic leukemia

机译:CD34和CD38是急性B淋巴细胞白血病的预后生物标志物

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

CD34 and CD38 proteins are usually used as surface markers to identify HSCs and Leukemic stem cells. However, there have been cases that lacked CD34 or CD38 protein but still had leukemia initiating capacity in B-ALL suggesting the restrictive of these two markers. CD34 and CD38 expression were detected in most B-ALL and can serve as a specific biomarker for the prognosis of this subset of leukemia. Lack of CD34 or high CD38 expression is associated with favorable prognosis.
机译:CD34和CD38蛋白通常用作表面标志物,以鉴定HSC和白血病干细胞。但是,有些病例缺乏CD34或CD38蛋白,但在B-ALL中仍具有白血病起始能力,提示这两个标记物具有限制性。在大多数B-ALL中检测到CD34和CD38的表达,可以作为该白血病亚型预后的特异性生物标志物。 CD34缺乏或CD38高表达与预后良好相关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号